4.5 Review

Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer

Journal

CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volume 209, Issue 1, Pages 22-32

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/cei/uxac028

Keywords

NKG2D; NKp30; NKp46; Fc gamma RIIIA; natural killer cells; bispecific antibody; CAR NK; CAR T

Categories

Funding

  1. Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [444949889]

Ask authors/readers for more resources

NK cells play a crucial role in cancer immune surveillance by recognizing malignant cells and controlling their activation through the expression of activating and inhibitory receptors. The recruitment and activation of NK cells have great potential in cancer treatment. Targeting the ligands expressed on tumors is also a promising approach to unleash the cytotoxicity of NK cells.
Natural killer (NK) cells exert an important role in cancer immune surveillance. Recognition of malignant cells and controlled activation of effector functions are facilitated by the expression of activating and inhibitory receptors, which is a complex interplay that allows NK cells to discriminate malignant cells from healthy tissues. Due to their unique profile of effector functions, the recruitment of NK cells is attractive in cancer treatment and a key function of NK cells in antibody therapy is widely appreciated. In recent years, besides the low-affinity fragment crystallizable receptor for immunoglobulin G (Fc gamma RIIIA), the activating natural killer receptors p30 (NKp30) and p46 (NKp46), as well as natural killer group 2 member D (NKG2D), have gained increasing attention as potential targets for bispecific antibody-derivatives to redirect NK cell cytotoxicity against tumors. Beyond modulation of the receptor activity on NK cells, therapeutic targeting of the respective ligands represents an attractive approach. Here, novel therapeutic approaches to unleash NK cells by engagement of activating NK-cell receptors and alternative strategies targeting their tumor-expressed ligands in cancer therapy are summarized.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available